The Real Cause Of Type 2 Diabetes (And How To Reverse It) | Roy Taylor

Episode Overview

• Professor Roy Taylor, MBE (Emeritus Professor of Medicine and Metabolism at Newcastle University and author of Life Without Diabetes) joins host Simon Hill to discuss the pathophysiology and durable remission of Type 2 diabetes, updating their conversation from three years prior.
• The discussion breaks down the "Twin Cycle Hypothesis" and "Personal Fat Threshold," explaining why Type 2 diabetes is fundamentally driven by excess fat spilling into the liver and pancreas rather than permanent pancreatic beta-cell death or complex multi-organ failure.
• Taylor presents the 5-year follow-up data from the landmark DiRECT trial and findings from the NHS England Type 2 Diabetes Path to Remission programme, illustrating how rapid weight loss affects long-term remission, hospitalization rates, and cancer incidence.
• The conversation critically evaluates modern pharmacological interventions—including GLP-1 receptor agonists, retatrutide, and myostatin inhibitors—contrasting pharmaceutical marketing claims with physiological realities, real-world adherence, and muscle-loss concerns.
• Finally, the episode explores the sharp rise in gestational diabetes since 1985, its underlying link to pre-existing liver fat, and how weight management during pregnancy impacts maternal and fetal outcomes.

Key Concepts

• The Personal Fat Threshold and Subcutaneous Storage: Humans have a finite, genetically determined capacity (governed by "50-odd genes") to store excess calories safely as subcutaneous fat under the skin. Once an individual exceeds their personal threshold, fat spills over into ectopic sites like the liver, meaning Type 2 diabetes is triggered by exceeding one's individual storage limit rather than a universal BMI cutoff.
• The Twin Cycle Hypothesis vs. The "Ominous Octet": Critiquing Ralph DeFronzo’s "Ominous Octet" as overcomplicated, Taylor emphasizes that only three components truly matter in Type 2 diabetes: the liver, muscle, and pancreatic beta cells (with other factors like the brain having a "tiny, tiny, tiny effect"). Excess liver fat triggers a vicious cycle of hepatic insulin resistance and increased fat export into the blood, which exposes pancreatic beta cells to roughly a 50% increase in fat supply and triggers a second vicious cycle that suppresses insulin secretion.
• Permissive Muscle Insulin Resistance vs. Driving Liver Fat: Healthy individuals store about 30% of meal carbohydrates in muscle as glycogen, whereas those with inherited muscle insulin resistance store much less, forcing the liver to convert unstored carbohydrate into fat. However, animal models lacking muscle insulin receptors do not develop diabetes, and human muscle insulin resistance barely changes even after diabetes remission; thus, muscle resistance merely sets the stage, while liver fat calls the shots. Because muscle remains insulin resistant after remission, regaining weight carries a 100% chance of redeveloping Type 2 diabetes.
• Rapid Hepatic Normalization: On the Newcastle diet (800 kilocalories per day of liquid soups and shakes), liver fat falls by about 30% within 7 days, toxic lipid intermediates like diglycerides disappear even faster, and liver insulin sensitivity becomes completely normal at 7 days. Total liver fat reaches normal levels (down to an average of 1.8% in the ReTUNE study) within 4 to 8 weeks.
• Beta-Cell Suppression vs. Apoptosis: Contrary to long-standing medical dogma based on short-span animal models, human pancreatic beta cells in Type 2 diabetes are not dead or undergoing apoptosis. Post-mortem pancreas studies confirm the cells are still present but suppressed by excess fat. If weight loss occurs within the first 6 years of diagnosis, about 90% of people can wake up these cells and reverse their diabetes; remission rates drop to about 50% after 10 years and to a very small percentage after 20 years (though Taylor has seen 2 patients with a 23-year history achieve tablet-free remission).
• Dietary Composition and Calorie Balance: In Western Europe, adult body weight rises by an average of 0.5 kg per year between ages 20 and 60, heavily driven by ultra-processed foods (which make up 55% of UK food intake). While laboratory cells exposed to saturated fat respond less well to insulin than those given unsaturated fat, human dietary studies on fat saturation are "relatively unimpressive" and Taylor notes he is still grappling with separating saturated fat from total calories in real food (noting also that human body fat is roughly 50% saturated and 50% monounsaturated/polyunsaturated, and butter is almost 50% monounsaturated fat). Similarly, while Dr. Nicola Guess’s research into amino acid sensing by beta cells is theoretically plausible, early tests show dietary protein cannot reach the beta cell fast enough to work clinically in Type 2 diabetes.
• Long-Term Durability and Health Outcomes (DiRECT & Look AHEAD): The dietetic belief that rapid weight loss causes rapid overshoot regain has no scientific evidence, and a May 2026 review in The Lancet Diabetes & Endocrinology by Magkos and Stefan confirms weight cycling (yo-yo dieting) is not clinically harmful. In the DiRECT trial, average weight loss was 15 kg after the initial 12-week liquid phase, 10 kg at 1 year (46% remission), 8.6 to 8.8 kg at 2 years (36% remission), and 6.3 kg at 5 years (13% remission across the total group). Even with partial regain, the 5-year intervention group had half (50% reduction) the hospital admissions and substantially fewer cancers than controls. While DiRECT's sample size was too small to directly show cardiac event differences, calculated 10-year heart disease risk normalized in remission patients, and the 12-year US Look AHEAD study showed that maintaining remission for 4 years reduced heart disease rates by "60-odd percent" (to about one-third).
• Demographic and Socioeconomic Factors in Remission: In both the DiRECT 5-year follow-up and the NHS England population study, men and women performed similarly, and older people maintained weight loss better than younger people. In the NHS England study, initial weight loss was equal across socioeconomic groups, but 1-year remission was about 31% in affluent areas compared to 19% in the most deprived areas. Furthermore, independent psychological evaluations showed no major psychological disbenefit among patients who lost weight and normalized liver fat/heart risk but failed to achieve diabetes remission.
• GLP-1 Agonists and New Pharmacotherapies: While pharmaceutical trials report 20% weight loss by pairing GLP-1 drugs with intensive lifestyle programs, real-life weight loss is about half that (~10 kg), at least 50% of patients stop taking them due to side effects (nausea, vomiting), and stopping leads to baseline weight return within 18 months (though Taylor hedges that a direct comparison between DiRECT and STEP-1 cannot be made without a head-to-head trial). A rare side effect is pancreatitis, requiring an average of 12 days in intensive care. Furthermore, Taylor critiques pharmaceutical marketing regarding an "incretin effect": while natural post-meal GLP-1 spikes add ~30% to peak insulin in healthy people, legally approved drug literature contains zero evidence that GLP-1 drugs increase mealtime insulin response; they work by suppressing brain appetite centers and draining liver/pancreatic fat. Regarding newer drugs like retatrutide (which includes a glucagon component), Taylor notes he cannot give a definitive answer on such a new drug, but argues physiologically that drugs cannot drive liver fat to a "supernormal" level below the 1.8% low-normal already achieved via 10 to 15 kg of dietary weight loss.
• The "Illusion" of Dietary Muscle Loss: Taylor describes fear surrounding muscle loss during rapid weight loss—and the push for myostatin inhibitors like apitegromab (which reduced lean mass loss by ~50% when paired with tirzepatide in the phase 2 EMBRAZE trial)—as "hysteria" and "illusory" when protein intake is adequate (though he notes scientists must keep an open mind). Wearing a 15 kg weighted vest for 8 weeks increases muscle mass by ~2%, so losing 15 kg of body weight naturally sheds that small load-bearing adaptation. Additionally, bioimpedance scales misinterpret water/fluid changes as lean mass loss.
• Gestational Diabetes as an Early Warning Sign: Appearing around the middle of pregnancy, gestational diabetes has risen dramatically since 1985 (when Taylor saw ~1 patient per year needing insulin, compared to needing a dedicated clinic today) and carries a ~50% lifetime risk of progressing to Type 2 diabetes. Risk factors include family history, Asian/Far Eastern or African ethnicity, and older maternal age. Studies of women between pregnancies reveal excess liver fat. While Taylor caveats that definitive medical proof isn't yet closed on pre-pregnancy weight loss preventing gestational diabetes, large population data from his group shows that losing weight after a gestational diabetes diagnosis halfway through pregnancy reduces the need for insulin and results in smaller babies, lowering caesarean section and pelvic floor damage rates.
• Disclosed Ties and Sponsors: Host Simon Hill discloses sponsorships with Upwork (freelancer platform; Business Plus), Function Health (lab testing service; 160+ tests/year for $1/day; code SIMON25 for $25 credit at functionhealth.com/simonhill), Momentous ("Signature Spec" creatine monohydrate; code THEPROOF for up to 35% off first order at livemomentous.com), and Skylight Calendar (myskylight.com/theproof for $30 off a 15-inch touchscreen calendar). Guest Professor Roy Taylor is the architect of the Newcastle diet, Counterpoint, DiRECT, ReTUNE, and the NHS England programme, with no commercial pharmaceutical ties disclosed.

Quotes

• At 0:01:39 - "Well, I'm very pleased to say that the, the central matter of the potential reversibility of type 2 diabetes is absolutely solid." - Taylor confirming that since first announcing the findings in 2011, Type 2 diabetes remission has moved from theory to established national clinical practice in England.
• At 0:03:43 - "And this was the idea that there was a cycle, a vicious cycle in the liver which started going, and that knocked on to a vicious cycle in the pancreas. And as they ground slowly on together, they would interact, the effect would be magnified, the end result was type 2 diabetes." - Taylor explaining the core mechanism of his 2008 Twin Cycle Hypothesis.
• At 0:12:08 - "Whereas pulling it apart with a physiological approach, we're able to see what really matters, and we're left with a much, much simpler model of the liver calling the shots, muscle being relevant, and the beta cell eventually turning up its toes." - Taylor simplifying DeFronzo's "Ominous Octet" down to the three organs that actually drive the disease.
• At 0:17:10 - "Then within seven days, their liver fat will have fallen about 30%." - Taylor describing the immediate hepatic response during the first week of an 800-kilocalorie-per-day liquid diet.
• At 0:17:46 - "The liver function as regards insulin sensitivity is completely normal at seven days. Now, that is staggering, that we can normalize the sensitivity of the liver." - Taylor highlighting how rapidly hepatic insulin resistance resolves once toxic lipid intermediates like diglycerides are cleared.
• At 0:20:00 - "No, people remain relatively insulin resistant in muscle after getting rid of the diabetes. What does that mean? It means that that sword of Damocles is still hanging over them. In other words, if their weight goes back up again, there is 100% chance that they will redevelop type 2 diabetes." - Taylor explaining why muscle insulin resistance persists after remission and why maintaining weight loss below the personal fat threshold is permanent.
• At 0:22:20 - "So the beta cell is suppressed, and no, it's not apoptosed and it's not dead. Those are both ideas that have been floated for a while." - Taylor debunking the myth that insulin-producing cells permanently die off in human Type 2 diabetes.
• At 0:25:50 - "On average, people in the first six years will be able to reverse their diabetes fine, about 90% of them, but after 10 years it's down to about 50%, and after 20 years it's a very small percentage." - Taylor detailing how the probability of waking up suppressed beta cells declines with disease duration.
• At 0:38:45 - "I would answer it by saying, no, there is no one diet that I would recommend for everybody, because individual preferences vary, and the way in which people can keep a reasonable limit on the total amount of food that they eat is going to vary." - Taylor emphasizing that long-term weight maintenance depends on personal preference rather than a single universal macronutrient ratio.
• At 0:44:25 - "Rapid weight loss is followed by rapid weight gain and people are going to overshoot. Now, that's one of these beliefs in the nutrition field which has absolutely no evidence." - Taylor refuting conventional dietetic wisdom using long-term clinical trial data.
• At 0:47:11 - "The number of admissions to hospital in the weight loss group was exactly half that in the ordinary group. So this is a profound effect on health, and even more than that, the number of cancers in the weight loss group was substantially reduced compared with the intervention group." - Taylor sharing the 5-year DiRECT trial follow-up outcomes on serious morbidity and hospitalizations.
• At 1:01:17 - "When the drug's stopped, the rate of weight gain is such that it's gone back to baseline within 18 months." - Taylor citing the STEP-1 trial extension data on weight regain following the withdrawal of semaglutide.
• At 1:08:05 - "These drugs do an amazing job at removing fat from the body. I can predict absolutely they will reduce liver fat, I can predict they'll reduce the secretion of fat from the liver, and they'll relieve the fat burden from the beta cell, which of course wakes up, but the idea that there's some magical incretin effect has always been something of a Cinderella." - Taylor clarifying that GLP-1 receptor agonists reverse diabetes by reducing ectopic fat via appetite suppression rather than directly boosting mealtime insulin secretion.
• At 1:14:33 - "This idea that rapid dietary weight loss with adequate protein supplementation produces muscle loss is illusory." - Taylor explaining why functional muscle is preserved during rapid weight loss when protein intake is sufficient and why bioimpedance scales mislead users.

Takeaways

• Act Within the First 6 Years of Diagnosis: Because beta-cell recovery rates drop from ~90% within the first 6 years to ~50% after 10 years, patients newly diagnosed with Type 2 diabetes should prioritize substantial weight loss (10 to 15 kg / ~2.5 stone) immediately rather than waiting for progressive medication escalation.
• Use a Structured 12-Week Reset to Clear Liver Fat: To break the Twin Cycle quickly, utilize a structured 12-week low-calorie liquid soup-and-shake protocol (800 kcal/day) with zero alcohol, which reduces liver fat by 30% and normalizes liver insulin sensitivity within 7 days.
• Track Liver Enzymes (ALT and GGT) as a Clinical Proxy: If you have elevated baseline liver function tests at diagnosis—specifically ALT over 40 and GGT over 35—monitor these markers during weight loss; normalizing them guarantees that you have successfully cleared your excess liver fat.
• Implement Pre-Planned "Rescue Packages" for Weight Regain: Expect life events to cause occasional weight creep and apply the DiRECT trial rescue protocol: if weight climbs by more than 2 kg, receive dietary support and replace one daily meal (such as dinner) with a liquid soup or shake; if weight climbs by more than 4 kg, return to the full soup-and-shake program for a brief period.
• Choose a Maintenance Diet Based on Personal Preference and Whole Foods: Once the initial weight-loss phase is complete, transition to whatever dietary pattern (Mediterranean, lower-carb, etc.) fits your personal preference and social life to prevent the average 0.5 kg/year adult weight creep, while actively avoiding appetite-fooling ultra-processed foods.
• Maintain Adequate Protein Intake on GLP-1s or Low-Calorie Diets: While regulated soup-and-shake packets contain over 25% protein to prevent functional muscle loss, individuals using GLP-1 medications and choosing their own smaller meals must deliberately prioritize protein intake to protect lean mass—and avoid relying on bioimpedance scales that misread fluid loss as muscle loss.
• Manage Weight Following a Gestational Diabetes Diagnosis: Women diagnosed with gestational diabetes halfway through pregnancy should work with their clinical team to prevent further weight gain or safely lose weight, which reduces the need for insulin, prevents overly large babies, and lowers the risk of caesarean sections and pelvic floor damage.
• Normalize Smaller Portions in Social Settings: Take advantage of shifting cultural norms—such as high-street bakeries offering downsized pastries and restaurants accommodating smaller appetites—by explicitly asking for smaller portions when dining out to stay below your personal fat threshold permanently.